gemcitabine + bosutinib

Gemcitabine + bosutinib is an investigational combination therapy consisting of two small molecule drugs with distinct mechanisms of action. Gemcitabine is a nucleoside analog and antimetabolite chemotherapeutic agent that inhibits DNA synthesis by incorporating into DNA during replication, leading to cell cycle arrest and apoptosis in rapidly dividing tumor cells. It is approved for use in several solid tumors, including pancreatic, ovarian, breast, bladder, and non-small cell lung cancers[1][4]. Bosutinib is a tyrosine kinase inhibitor targeting BCR-ABL (the fusion protein driving Philadelphia chromosome-positive chronic myelogenous leukemia) as well as SRC family kinases. It blocks the ATP-binding site of these kinases to inhibit their activity and downstream signaling pathways involved in cancer cell proliferation and survival[3]. The combination of gemcitabine with other targeted agents has been explored to enhance antitumor efficacy; however, there are no published clinical trials or regulatory approvals specifically for the combination of gemcitabine plus bosutinib as of May 2025.